Cost-effectiveness of routine vaccination of adolescent females against cytomegalovirus

摘要: Abstract Background Congenital cytomegalovirus (CMV) infection is associated with significant infant morbidity and mortality. A prophylactic vaccine to prevent congenital CMV expected be available in the near future, will likely targeted adolescent females. Methods Using a decision tree, we compared costs, potential clinical impacts, cost-effectiveness of current strategy no vaccination versus where all females are vaccinated against prior their first pregnancy. Both maternal outcomes related vaccination, infection, were considered model. Results Under base-case conditions, our analysis suggested that vaccinating would both less costly greater benefits than not vaccinating. Among population 100,000 females, cost $32.3 million dollars vaccinating, avoided substantial numbers infants affected hearing loss, vision mental retardation, 8 deaths. Our model was most sensitive variations efficacy. When efficacy disease 61%, became preferred because it expensive without changes population. Conclusions wide variety universal protect future children effective. However, for this over results suggest need at least 61%.